News
News GlobeNewswire Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback